eClinical

Five industry leaders share their perspectives on the evolution of DCTs.

Designing eConsent for each study from a stakeholders’ value, not technology perspective.

After a period of "fits and starts," large pharma companies are increasingly investing in digital health tools to reach business goals, be they through internal investments or strategic partnerships.

Key considerations in deploying fit-for-purpose digital health technologies in drug development.

Factors that contribute to Japan's prominent position in the rapidly evolving field of digital therapeutics and why it matters to the global life sciences industry.

Harnessing advances in digital health technologies for a more precision-measured approach.

Harnessing these tools for successful integration and streamlining of processes.

An increasing number of patients report looking for more simplicity and less burden related to a clinical trial, and a "bring your own device" option is one of the ways to meet this need

Fostering common eConsent terminologies enriches communication and understanding across all stakeholders.

Emerging technologies like digital twins offer supply chain efficiency solutions, allowing the industry to integrate sustainable practices while ensuring patient safety.

Unraveling eConsent Ethics Committees and Health Authorities submission document requirements to foster wider adoption.

Interactive panel discussed the evolving area of data transfer and the usage of EHR-to-EDC.

Industry leaders gathered to address the current landscape of data collection in clinical trials.

Artificial intelligence may find a home in clinical trials and manufacturing in the coming years, but privacy, cyber security, and determining who owns the intellectual properties could pose challenges.

Even with exciting advancements, stakeholders must remain diligent in choosing data platforms.

Harmonization and value insights are fundamental to bring eConsent to the place it deserves.

Key considerations for successful implementation in decentralized clinical trials.

In this Q&A, leaders from Bioforum, KCR, Syneos Health, and Veeva come together to share insights on the state of digital clinical trials and how the industry will evolve over the next couple of years.

EU Medical Device Regulation must be followed carefully as it leaves room for interpretation.

Melissa Easy, VP and GM, clinical technologies at IQVIA speaks about concerns with clinical technology at the SCOPE 2023 conference in Orlando, FL.

How evidence generated by the latest IgniteData ‘real-setting’ pilot study supports the case for clinical trial transformation.

Sam Whitaker, co-founder and co-CEO of Mural Health discusses his time in the industry and patient needs in the current clinical trials market.

Providing patients with more flexibility in how they choose to participate in trials.

Good scientific principles and practices are essential for maintaining quality data that patients can benefit from.

Survey results emphasize need for flexibility in strategies.

Lindsay Hughes, PhD, principal scientific advisor of Clario discusses the current eCOA environment, new technology applications, and how technology implementations should be supported by science.

Industry now leveraging reporting system to empower patients and improve research.

The many different shapes and sizes of vendors requires a thoughtful process for selection.

All stakeholders must play part in increasing implementation.

While eConsent has become more widely adopted since COVID-19, work still needs to be done in improving patients’ understanding.